Rodman & Renshaw Initiates Coverage on Leap Therapeutics (NASDAQ:LPTX)

Rodman & Renshaw assumed coverage on shares of Leap Therapeutics (NASDAQ:LPTX) in a report issued on Friday, MarketBeat reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Rodman & Renshaw’s price target suggests a potential upside of 308.16% from the stock’s current price.

Several other research analysts have also issued reports on the company. HC Wainwright cut their price target on Leap Therapeutics from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Tuesday, May 14th. Robert W. Baird cut their price target on Leap Therapeutics from $11.00 to $9.00 and set an “outperform” rating on the stock in a report on Tuesday, March 19th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Leap Therapeutics has a consensus rating of “Buy” and an average price target of $10.40.

Leap Therapeutics Price Performance

Shares of Leap Therapeutics stock opened at $1.96 on Friday. Leap Therapeutics has a one year low of $1.24 and a one year high of $5.00. The stock’s 50-day moving average is $2.53 and its 200 day moving average is $2.87. The firm has a market cap of $50.18 million, a price-to-earnings ratio of -0.82 and a beta of 0.41.

Leap Therapeutics (NASDAQ:LPTX) last announced its earnings results on Monday, May 13th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.06. On average, sell-side analysts expect that Leap Therapeutics will post -1.66 EPS for the current fiscal year.

Institutional Trading of Leap Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LPTX. Key Client Fiduciary Advisors LLC raised its stake in shares of Leap Therapeutics by 43.3% in the third quarter. Key Client Fiduciary Advisors LLC now owns 227,273 shares of the company’s stock worth $314,000 after purchasing an additional 68,676 shares during the last quarter. Acuta Capital Partners LLC purchased a new stake in shares of Leap Therapeutics during the third quarter valued at approximately $489,000. 683 Capital Management LLC increased its position in shares of Leap Therapeutics by 60.7% during the third quarter. 683 Capital Management LLC now owns 490,000 shares of the company’s stock valued at $676,000 after acquiring an additional 185,001 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Leap Therapeutics by 349.3% during the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock valued at $750,000 after acquiring an additional 219,563 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Leap Therapeutics by 111.7% during the first quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock valued at $2,308,000 after acquiring an additional 457,904 shares during the last quarter. 30.46% of the stock is owned by hedge funds and other institutional investors.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.